Mannkind Corporation (NASDAQ: MNKD) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT MANNKIND CORPORATION

Mannkind Corporation (NASDAQ: MNKD)
Listen to this Section


$5.74
+0.1450 ( +2.23% ) 569.3K

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Market Data


Open $5.74
Previous Close $5.59
Volume 569.3K
Market Cap $1.56B
Day Range $5.54 - $5.75
52 Week Range $3.22 - $7.63
Shares Outstanding 275.78M
Change % +2.23%
Net Change ▲ 0.1450
Insider Ownership -0.03%
Exchange NASDAQ
Sector Miscellaneous
Industry None
IPO Year 2004
Country United States

Insider Ownership Transactions

Total Amount Purchased: -2,537,675.00

Date Type Amount Purchased Purchaser
2024-07-17 Sale -800.00 Binder Steven B.
2024-07-17 Sale -5000.00 Castagna Michael
2024-07-17 Sale -3362.00 Singh Sanjay R
2024-07-17 Sale -722.00 Sabella Lauren M
2024-07-17 Sale -12616.00 Thomson David
2024-07-17 Sale -4689.00 Tross Stuart A
2024-05-29 Sale -16151.00 BLANK BURKHARD
2024-05-21 Sale -221480.00 Castagna Michael
2024-05-21 Sale -77420.00 Binder Steven B.
2024-05-21 Sale -77420.00 Thomson David

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 11 Jan 06, 2025
8-k 8K-related 13 Dec 18, 2024
4 Insider transactions 1 Nov 25, 2024
4 Insider transactions 1 Nov 19, 2024
4 Insider transactions 1 Nov 08, 2024
10-q Quarterly Reports 114 Nov 07, 2024
8-k 8K-related 13 Nov 07, 2024
4 Insider transactions 1 Nov 04, 2024
4 Insider transactions 1 Sep 04, 2024
4 Insider transactions 1 Aug 30, 2024

Latest News


× Before browsing our site, please accept our cookies policy